Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
55.84
+0.04 (0.07%)
Mar 6, 2026, 10:51 AM EST - Market open
Monopar Therapeutics Employees
As of December 31, 2024, Monopar Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 6 or 60.00% compared to the previous year.
Employees
16
Change (1Y)
6
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,215,107
Market Cap
373.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aura Biosciences | 109 |
| Neurogene | 107 |
| Aclaris Therapeutics | 73 |
| Atea Pharmaceuticals | 56 |
| Candel Therapeutics | 38 |
| NovaBridge Biosciences | 32 |
| Benitec Biopharma | 19 |
| Climb Bio | 18 |
MNPR News
- 4 days ago - Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - GlobeNewsWire
- 4 months ago - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - GlobeNewsWire
- 4 months ago - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 5 months ago - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 5 months ago - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 months ago - Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - GlobeNewsWire
- 6 months ago - Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting - GlobeNewsWire
- 6 months ago - Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent - Seeking Alpha